A carregar...
Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
INTRODUCTION: Body weight can affect exposure, safety and efficacy of antibody-based therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved for wild-type RAS metastatic colorectal cancer, using a body weight–based dosing regimen. Recently, a report cited fixed-dos...
Na minha lista:
| Publicado no: | Clin Pharmacol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7406372/ https://ncbi.nlm.nih.gov/pubmed/32801947 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CPAA.S262949 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|